Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
Abstract Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T...
Zapisane w:
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMC
2024-07-01
|
| Seria: | Cardiovascular Diabetology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1186/s12933-024-02328-6 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|